参考文献/References:
[1] Li D,Yang Y,Wang S,et al. Role of acetylation in doxorubicin-induced cardiotoxicity[J]. Redox Biol,2021,46:102089.
[2] Agha A,Wang X,Wang M,et al. Long-term risk of death from heart disease among breast cancer patients[J]. Front Cardiovasc Med,2022,9:784409.
[3] Mamic P,Lanfear DE. Gut microbiome in cardiovascular disease and heart?failure:seeing the iceberg below its surface[J]. JACC Heart Fail,2023,11(7):822-824.
[4] 王青伟,丁荣晶. 阿霉素诱导心脏毒性的发病机制与防治[J]. 自然杂志,2022,44(2):103-108.
[5] Marinello J,Delcuratolo M,Capranico G. Anthracyclines as topoisomerase Ⅱ poisons:from early studies to new perspectives[J]. Int J Mol Sci,2018,19(11):3480.
[6] Fang X,Wang H,Han D,et al. Ferroptosis as a target for protection against cardiomyopathy[J]. Proc Natl Acad Sci U S A,2019,116(7):2672-2680.
[7] Tadokoro T,Ikeda M,Ide T,et al. Mitochondria-dependent ferroptosis plays a pivotal role in doxorubicin cardiotoxicity[J]. JCI Insight,2020,5(9):e132747.
[8] Younis NS,Elsewedy HS,Soliman WE,et al. Geraniol isolated from lemon grass to mitigate doxorubicin-induced cardiotoxicity through Nrf2 and NF-κB signaling[J]. Chem Biol Interact,2021,347:109599.
[9] Li X,Luo W,Tang Y,et al. Semaglutide attenuates doxorubicin-induced cardiotoxicity by ameliorating BNIP3-Mediated mitochondrial dysfunction[J]. Redox Biol,2024,72:103129.
[10] Zhang Y,Ahmad KA,Khan FU,et al. Chitosan oligosaccharides prevent doxorubicin-induced oxidative stress and cardiac apoptosis through activating p38 and JNK MAPK mediated Nrf2/ARE pathway[J]. Chem Biol Interact,2019,305:54-65.
[11] Shinlapawittayatorn K,Chattipakorn SC,Chattipakorn N. The effects of doxorubicin on cardiac calcium homeostasis and contractile function[J]. J Cardiol,2022,80(2):125-132.
[12] Huang J,Wei S,Jiang C,et al. Involvement of abnormal gut microbiota composition and function in doxorubicin-induced cardiotoxicity[J]. Front Cell Infect Microbiol,2022,12:808837.
[13] AL-Qadami GH,Secombe KR,Subramaniam CB,et al. Gut microbiota-derived short-chain fatty acids:impact on cancer treatment response and toxicities[J]. Microorganisms,2022,10(10):2048.
[14] Russo M,Guida F,Paparo L,et al. The novel butyrate derivative phenylalanine-butyramide protects from doxorubicin-induced cardiotoxicity[J]. Eur J Heart Fail,2019,21(4):519-528.
[15] Liu J,Fu W,Wang X,et al. The role of HDAC2 inhibition in cardioprotection against doxorubicin-induced myocardial injury[J]. Front Cardiovasc Med,2025,12:1557119.
[16] Jiang L,Wang J,Liu Z,et al. Sodium Butyrate Alleviates lipopolysaccharide-induced inflammatory responses by down-regulation of nf-κb, nlrp3 signaling pathway, and activating histone acetylation in bovine macrophages[J]. Front Vet Sci,2020,7:579674.
[17] Mann ER,Lam YK,Uhlig HH. Short-chain fatty acids:linking diet, the microbiome and immunity[J]. Nat Rev Immunol,2024,24(8):577-595.
[18] Chen H,Qian Y,Jiang C,et al. Butyrate ameliorated ferroptosis in ulcerative colitis through modulating Nrf2/GPX4 signal pathway and improving intestinal barrier[J]. Biochim Biophys Acta Mol Basis Dis,2024,1870(2):166984.
[19] Lu LL,Liu LZ,Li L,et al. Sodium butyrate improves cognitive dysfunction in high-fat diet/ streptozotocin-induced type 2 diabetic mice by ameliorating hippocampal mitochondrial damage through regulating AMPK/PGC-1α pathway[J]. Neuropharmacology,2024,261:110139.
[20] Li X, Wang C, Zhu J, et al. Sodium butyrate ameliorates oxidative stress-induced intestinal epithelium barrier injury and mitochondrial damage through ampk-mitophagy pathway[J]. Oxid Med Cell Longev,2022,2022:3745135.
[21] Zhang H,Pan J,Huang S,et al. Hydrogen sulfide protects cardiomyocytes from doxorubicin-induced ferroptosis through the SLC7A11/GSH/GPx4 pathway by Keap1 S-sulfhydration and Nrf2 activation[J]. Redox Biol,2024,70:103066.
[22] Hanson BT,Dimitri Kits K,L?ffler J,et al. Sulfoquinovose is a select nutrient of prominent bacteria and a source of hydrogen sulfide in the human gut[J]. ISME J,2021,15(9):2779-2791.
[23] Ye X,Li Y,Lv B,et al. Endogenous hydrogen sulfide persulfidates caspase-3 at cysteine 163 to inhibit doxorubicin-induced cardiomyocyte apoptosis[J]. Oxid Med Cell Longev,2022,2022:6153772.
[24] Zhang B,Li Y,Liu N,et al. AP39,a novel mitochondria-targeted hydrogen sulfide donor ameliorates doxorubicin-induced cardiotoxicity by regulating the AMPK/UCP2 pathway[J]. Plos One,2024,19(4):e0300261.
[25] Wang Y,Ying X,Wang Y,et al. Hydrogen sulfide alleviates mitochondrial damage and ferroptosis by regulating OPA3-NFS1 axis in doxorubicin-induced cardiotoxicity[J]. Cell Signal,2023,107:110655.
[26] Tomasova L,Konopelski P,Ufnal M. Gut bacteria and hydrogen sulfide:the new old players in circulatory system homeostasis[J]. Molecules,2016,21(11):1558.
[27] Li J,Zhang L,Wu T,et al. Indole-3-propionic acid improved the intestinal barrier by enhancing epithelial barrier and mucus barrier[J]. J Agric Food Chem,2021,69(5):1487-1495.
[28] Li C,Chang J,Wang Y,et al. Indole-3-propionic acid,a product of intestinal flora, inhibits the HDAC6/NOX2 signaling and relieves doxorubicin-induced cardiomyocyte damage[J]. Folia Morphol (Warsz),2024,83(2):382-390.
[29] Wang YC,Koay YC,Pan C,et al. Indole-3-propionic acid protects against heart failure with preserved ejection fraction[J]. Circ Res,2024,134(4):371-389.
[30] Zhang Y,Li S,Fan X,et al. Pretreatment with indole-3-propionic acid attenuates lipopolysaccharide-induced cardiac dysfunction and inflammation through the AhR/NF-κB/NLRP3 pathway[J]. J Inflamm Res,2024,17:5293-5309.
[31] Gesper M,Nonnast ABH,Kumowski N,et al. Gut-derived metabolite indole-3-propionic acid modulates mitochondrial function in cardiomyocytes and alters cardiac function[J]. Front Med (Lausanne),2021,8:648259.
[32] Zhao Z,Jiang S,Fan Q,et al. Apocynum venetum leaf extract alleviated doxorubicin-induced cardiotoxicity by regulating organic acid metabolism in gut microbiota[J]. Front Pharmacol,2023,14:1286210.
[33] Huang R,Shen ZY,Huang D,et al. Microbiota-indole-3-propionic acid-heart axis mediates the protection of leflunomide against αPD1-induced cardiotoxicity in mice[J]. Nat Commun,2025,16(1):2651.
[34] She J,Tuerhongjiang G,Guo M,et al. Statins aggravate insulin resistance through reduced blood glucagon-like peptide-1 levels in a microbiota-dependent manner [J]. Cell Metab,2024,36(2):408-421.e5.
[35] Fang Y,Yan C,Zhao Q,et al. The roles of microbial products in the development of colorectal cancer:a review[J]. Bioengineered,2021,12(1):720-735.
[36] Mihajlovi? D,?ukanovi? ?,Gaji? Boji? M,et al. Cardioprotective effects of ursodeoxycholic acid in isoprenaline-induced myocardial injury in rats[J]. Biomolecules,2024,14(10):1214.
[37] 王皓,夏薇薇,龙广凤,等. 熊去氧胆酸对阿霉素诱导的H9c2心肌细胞的影响及机制研究[J]. 现代生物医学进展,2021,21(3):418-423.
[38] Stephenson E,Mclaughlin M,Bray JW,et al. Nutrition modulation of cardiotoxicity in breast cancer:a scoping review[J]. Nutrients,2024,16(21):3777.
[39] Zhao X,Feng X,Ye N,et al. Protective effects and mechanism of coenzyme Q10 and vitamin C on doxorubicin-induced gastric mucosal injury and effects of intestinal flora[J]. Korean J Physiol Pharmacol,2021,25(4):261-272.
[40] Wu X,Zhang N,Kan J,et al. Polyphenols from Arctium lappa L ameliorate doxorubicin-induced heart failure and improve gut microbiota composition in mice [J]. J Food Biochem,2022,46(3):e13731.
[41] Niu H,Zhou M,Zogona D,et al. Akkermansia muciniphila:a potential candidate for ameliorating metabolic diseases[J]. Front Immunol,2024,15:1370658.
[42] Lin H,Shao X,Gu H,et al. Akkermansia muciniphila ameliorates doxorubicin-induced cardiotoxicity by regulating PPARα-dependent mitochondrial biogenesis[J]. NPJ Biofilms Microbiomes,2025,11(1):86.
[43] Zhou J,Hao J,Zhong Z,et al. Fecal microbiota Transplantation in mice exerts a protective effect against doxorubicin-induced cardiac toxicity by regulating Nrf2-Mediated cardiac mitochondrial fission and fusion[J]. Antioxid Redox Signal,2024,41(1-3):1-23.
[44] Lu G,Wang W,Li P,et al. Washed preparation of faecal microbiota changes the transplantation related safety, quantitative method and delivery[J]. Microb Biotechnol,2022,15(9):2439-2449.
相似文献/References:
[1]祁小青 周蕾.肿瘤治疗所致Ⅰ型心脏损伤的防治[J].心血管病学进展,2020,(7):741.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.017]
QI Xiaoqing,ZHOU Lei.Prevention and Treatment of TypeCardiac Injury Caused by Cancer Treatment[J].Advances in Cardiovascular Diseases,2020,(11):741.[doi:10.16806/j.cnki.issn.1004-3934.2020.07.017]
[2]唐雨琦 关旭敏 方凤奇 刘基巍 夏云龙.吉西他滨引起心脏毒性的研究现状[J].心血管病学进展,2020,(9):895.[doi:10.16806/j.cnki.issn.1004-3934.2020.09.002]
TANG Yuqi,GUAN Xumin,FANG Fengqi,et al.Cardiotoxicity Induced by Gemcitabine[J].Advances in Cardiovascular Diseases,2020,(11):895.[doi:10.16806/j.cnki.issn.1004-3934.2020.09.002]
[3]赵恒 谭琦 杜晓宇 谷泽慧 王亚帝.蒽环类药物致心脏毒性潜在的生物标志物研究[J].心血管病学进展,2022,(3):282.[doi:10.16806/j.cnki.issn.1004-3934.2022.03.000]
ZHAO HengTAN QiDU XiaoyuGU ZehuiWANG Yadi.Potential Biomarkers of Anthracycline-Induced Cardiotoxicity[J].Advances in Cardiovascular Diseases,2022,(11):282.[doi:10.16806/j.cnki.issn.1004-3934.2022.03.000]
[4]古力尼尕尔·麦麦提吐尔孙 付真彦.肺癌靶向治疗药物EGFR-TKI与其心脏毒性的研究进展[J].心血管病学进展,2022,(2):128.[doi:10.16806/j.cnki.issn.1004-3934.2022.02.009]
GULINIGAER·Maimaitituersun,FU Zhenyan.EGFR-TKI and Its Cardiotoxicity in Lung Cancer[J].Advances in Cardiovascular Diseases,2022,(11):128.[doi:10.16806/j.cnki.issn.1004-3934.2022.02.009]
[5]杨懿 牟云飞 任福强 黄鑫 王园.表皮生长因子受体酪氨酸激酶抑制剂用于非小细胞肺癌术后辅助治疗的心脏毒性回顾性分析[J].心血管病学进展,2022,(8):763.[doi:10.16806/j.cnki.issn.1004-3934.2022.08.023]
YANG Yi,MU Yunfei,REN Fuqiang,et al.A Retrospective Analysis of EGFR-TKIs-Induced Cardiotoxicity in Postoperative Adjuvant Therapy for Non-Small Cell Lung Cancer[J].Advances in Cardiovascular Diseases,2022,(11):763.[doi:10.16806/j.cnki.issn.1004-3934.2022.08.023]
[6]代虎威 王馨焱 李松珊 温泽宇 曾康 杨滨.免疫检查点抑制剂相关心肌炎的诊断及管理研究进展[J].心血管病学进展,2022,(10):937.[doi:10.16806/j.cnki.issn.1004-3934.2022.10.017]
Immune Checkpoint Inhibitor-Associated Myocarditis.Diagnosis and Management of[J].Advances in Cardiovascular Diseases,2022,(11):937.[doi:10.16806/j.cnki.issn.1004-3934.2022.10.017]
[7]邓悦 周晓阳.免疫检查点抑制剂相关心脏毒性的临床特点及研究进展[J].心血管病学进展,2023,(10):905.[doi:10.16806/j.cnki.issn.1004-3934.2023.10.010]
DENG YueZHOU Xiaoyang?/html>.Clinical Characteristics and Progress of?ardiac Toxicity Associated with Immune Checkpoint Inhibitors[J].Advances in Cardiovascular Diseases,2023,(11):905.[doi:10.16806/j.cnki.issn.1004-3934.2023.10.010]
[8]赵 珂 陈晓姝 魏希进 张 娟 刘 杨 卞雨敬 袁 杰.铁死亡的调控机制及其在蒽环类药物心脏毒性中的研究进展[J].心血管病学进展,2024,(3):261.[doi:10.16806/j.cnki.issn.1004-3934.202.03.016]
First Clinical Medical College,Shandong University of Traditional Chinese Medicine,Jinan 0000,et al.Regulatory Mechanism of Ferroptosis and Its Progress in Anthracycline-Induced Cardiotoxicity[J].Advances in Cardiovascular Diseases,2024,(11):261.[doi:10.16806/j.cnki.issn.1004-3934.202.03.016]
[9]李登科 张伟 黄从新.黄芩苷通过调节Nrf2/HO-1信号通路减轻阿霉素诱导的H9c2细胞毒性[J].心血管病学进展,2024,(5):457.[doi:10.16806/j.cnki.issn.1004-3934.2024.05.017]
LI Dengke,ZHANG Wei,HUANG Congxin.Baicalin Reduces Doxorubicin Induced H9c2 Cell Toxicity by Regulating the Nrf2/HO-1 Signaling Pathway[J].Advances in Cardiovascular Diseases,2024,(11):457.[doi:10.16806/j.cnki.issn.1004-3934.2024.05.017]
[10]柴雪祯 曹中伟 ?/html>.胰岛素样生长因子2受体在曲妥珠单抗治疗乳腺癌相关心脏毒性中的作用与机制研究[J].心血管病学进展,2025,(1):51.[doi:10.16806/j.cnki.issn.1004-3934.2025.01.012]
CHAI Xuezhen,CAO Zhongwei.Role and Mechanism of Insulin-Like Growth Factor 2 Receptor in Cardiotoxicity Associated with Trastuzumab Treatment of Breast Cancer[J].Advances in Cardiovascular Diseases,2025,(11):51.[doi:10.16806/j.cnki.issn.1004-3934.2025.01.012]
[11]王鹏 王鑫 张瑶 张经泽 贺世豪 李瑾.内质网应激在阿霉素心脏毒性中作用的研究进展[J].心血管病学进展,2023,(4):341.[doi:10.16806/j.cnki.issn.1004-3934.2023.04.012]
WANG Peng,WANG Xin,ZHANG Yao,et al.Role of Endoplasmic Reticulum Stress?n the Cardiotoxicity of Doxorubicin[J].Advances in Cardiovascular Diseases,2023,(11):341.[doi:10.16806/j.cnki.issn.1004-3934.2023.04.012]
[12]李登科 张伟 黄从新.SIRT1介导的信号通路在阿霉素诱导心脏毒性中的作用机制[J].心血管病学进展,2024,(3):257.[doi:10.16806/j.cnki.issn.1004-3934.2024.03.015]
LI Dengke,ZHANG Wei,HUANG Congxin.The Mechanisms of SIRT1-Mediated Signal Pathway in Doxorubicin-Induced Cardiotoxicity[J].Advances in Cardiovascular Diseases,2024,(11):257.[doi:10.16806/j.cnki.issn.1004-3934.2024.03.015]
[13]王心雨 王钰淇 罗皓文 常盼 赵晓红.线粒体质量控制在阿霉素诱导的心脏毒性中的研究进展[J].心血管病学进展,2025,(4):318.[doi:10.16806/j.cnki.issn.1004-3934.2025.04.008]
WANG Xinyu,WANG Yuqi,LUO Haowen,et al.Research Progress of Mitochondrial Quality Control in Doxorubicin Cardiotoxicity[J].Advances in Cardiovascular Diseases,2025,(11):318.[doi:10.16806/j.cnki.issn.1004-3934.2025.04.008]